231 related articles for article (PubMed ID: 6146602)
1. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects.
Richelson E
J Clin Psychiatry; 1984 Aug; 45(8):331-6. PubMed ID: 6146602
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of neuroleptics in use in the United States.
Richelson E
J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):8-14. PubMed ID: 2862140
[TBL] [Abstract][Full Text] [Related]
3. Interactions of neuroleptic metabolites with dopaminergic, alpha adrenergic and muscarinic cholinergic receptors.
Bylund DB
J Pharmacol Exp Ther; 1981 Apr; 217(1):81-6. PubMed ID: 6110776
[TBL] [Abstract][Full Text] [Related]
4. [Neuroleptics in geriatrics. Pharmacological criteria for a responsible choice and a correct use].
van Wielink PS
Tijdschr Gerontol Geriatr; 1984 Apr; 15(2):73-80. PubMed ID: 6144201
[TBL] [Abstract][Full Text] [Related]
5. Neuroleptic binding to human brain receptors: relation to clinical effects.
Richelson E
Ann N Y Acad Sci; 1988; 537():435-42. PubMed ID: 2904784
[TBL] [Abstract][Full Text] [Related]
6. [Profile of the adverse effects of neuroleptic drugs in relation to its receptor binding].
Gerlach J
Nord Med; 1987; 102(4):120-3. PubMed ID: 2884620
[No Abstract] [Full Text] [Related]
7. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic drugs: prediction of side-effect profiles based on neuroreceptor data derived from human brain tissue.
Black JL; Richelson E
Mayo Clin Proc; 1987 May; 62(5):369-72. PubMed ID: 2883343
[TBL] [Abstract][Full Text] [Related]
9. Amitriptylinoxide: receptor-binding profile compared with other antidepressant drugs.
Borbe HO; Zierenberg O
Pharmacopsychiatry; 1985 Sep; 18(5):314-9. PubMed ID: 2996040
[TBL] [Abstract][Full Text] [Related]
10. Relative affinities for different classes of neurotransmitter receptors predict neuroleptic efficacy in infantile autism: a hypothesis.
Deutsch SI; Campbell M
Neuropsychobiology; 1986; 15(3-4):160-4. PubMed ID: 2431345
[TBL] [Abstract][Full Text] [Related]
11. Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites.
Hals PA; Hall H; Dahl SG
Life Sci; 1988; 43(5):405-12. PubMed ID: 2899826
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of antipsychotic drugs.
Borison RL
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):25-8. PubMed ID: 2858475
[TBL] [Abstract][Full Text] [Related]
13. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents.
Buckley PF
J Clin Psychiatry; 2007; 68 Suppl 6():5-9. PubMed ID: 17650053
[TBL] [Abstract][Full Text] [Related]
14. Receptor pharmacology of neuroleptics: relation to clinical effects.
Richelson E
J Clin Psychiatry; 1999; 60 Suppl 10():5-14. PubMed ID: 10340682
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacology of neuroleptics: focus on new generation compounds.
Richelson E
J Clin Psychiatry; 1996; 57 Suppl 11():4-11. PubMed ID: 8941166
[TBL] [Abstract][Full Text] [Related]
16. Are receptor studies useful for clinical practice?
Richelson E
J Clin Psychiatry; 1983 Sep; 44(9 Pt 2):4-9. PubMed ID: 6313632
[TBL] [Abstract][Full Text] [Related]
17. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
Silvestre JS; Prous J
Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):289-304. PubMed ID: 16082416
[TBL] [Abstract][Full Text] [Related]
18. The pharmacology of antidepressants at the synapse: focus on newer compounds.
Richelson E
J Clin Psychiatry; 1994 Sep; 55 Suppl A():34-9; discussion 40-1, 98-100. PubMed ID: 7961541
[TBL] [Abstract][Full Text] [Related]
19. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Millan MJ; Maiofiss L; Cussac D; Audinot V; Boutin JA; Newman-Tancredi A
J Pharmacol Exp Ther; 2002 Nov; 303(2):791-804. PubMed ID: 12388666
[TBL] [Abstract][Full Text] [Related]
20. Role of serotonin and dopamine receptor binding in antipsychotic efficacy.
Richtand NM; Welge JA; Logue AD; Keck PE; Strakowski SM; McNamara RK
Prog Brain Res; 2008; 172():155-75. PubMed ID: 18772032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
